Integral BioSystems Announces its Drug Delivery, Formulation Development and IP Services

June 14, 2009 - PRLog -- Bedford, MA
Integral BioSystems, a contract research organization in the Boston area announced today to the Biotech community that it has launched its drug delivery, formulation development and IP services functionalities. The company is headquartered in Bedford, Massachusetts, and its state-of-the-art laboratories are in Littleton, Massachusetts.

The company specializes in the design and development of dosage forms for ophthalmic, transdermal, intravenous, intranasal and oral routes of drug administration. Furthermore, the company offers intellectual property and contracts development/negotiation services.

“Integral BioSystems excels in the conceptualization and design of drug development solutions for drug candidates that are challenging to deliver. These challenges include inherent insolubility of the drug, intrinsic tissue impermeability of the drug, and incompatibility with physiological fluids.  Our services also include the development of sustained release systems, such as microspheres, nanospheres, liposomes, depots, etc.  We hope to form liaisons and collaborations with start-ups and larger companies alike,” said David Karasic, Chief Intellectual Property & Business Development Officer.

About Integral BioSystems, LLC

Integral BioSystems, LLC was founded in 2008 by experienced drug development and patent professionals. The company has adopted a translational medicinal approach to drug development, customizing delivery systems to accomplish the biologically effective objectives of the therapy.  Delivery systems are customized to achieve sustained release or targeted, tissue-focused delivery, or fast-release/instant delivery, depending upon the desired product attributes.
Once the drug-containing formulations are tested in preclinical models, an integrated CMC plan is developed to systematically transition the project to scale up and product development. As part of product development, Integral BioSystems specializes in efficiently developing a dosage form to manufacture and test in Phase I/Phase II first-in-man trials for proof-of-concept.  The company has a network of manufacturers / analytical houses for pharmaceutics, that can fast-track the manufacture and release of the sterile dosage form for first-in-man trials.

Contact:
David Karasic
Chief Intellectual Property and Business Development Officer
Integral BioSystems, LLC
781-879-4677

# # #

A Boston area-based contract research organization, Integral BioSystems specializes in the development of ophthalmic, transdermal, intravenous, intranasal and oral dosage forms. Additionally, we offer services in intellectual property and contracts.